Published • loading... • Updated
Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion
- Shanghai Fosun Pharmaceutical plans to repurchase up to HK$1 billion of its H-shares.
- The repurchased shares will either be cancelled or held as treasury shares.
- The repurchase plan demonstrates management's strong confidence in the company's intrinsic value.
- The repurchase will be funded mainly by proceeds from selling about a 6% equity interest in Gland Pharma.
Insights by Ground AI
22 Articles
22 Articles
The Berkshire Eagle+20 Reposted by 20 other sources
Fosun Pharma Announces H-Share Repurchase Plan of Up to HK$ 1 Billion
SHANGHAI, Sept. 6, 2026 /PRNewswire/ -- Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ("Fosun Pharma", stock code: 600196.SH; 02196.HK) today announced an H-share repurchase plan, under which the company intends to repurchase its H-shares with an aggregate amount of up to…
Coverage Details
Total News Sources22
Leaning Left2Leaning Right4Center13Last UpdatedBias Distribution68% Center
Bias Distribution
- 68% of the sources are Center
68% Center
11%
C 68%
R 21%
Factuality
To view factuality data please Upgrade to Premium
